« BACK

Tuesday, December 1, 2009 :: Imaging Diagnostic Systems Exhibits CT Laser Mammography (CTLM) System at the 95th Annual Radiological Society of North America (RSNA) Scientific Assembly
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Imaging Diagnostic Systems, Inc., (OTCBB:IMDS - News), a pioneer in laser optical breast imaging, announced today that it is exhibiting its CTLM system and clinical case studies at the 95th annual meeting of the Radiological Society of North America (RSNA) 2009, November 29th – December 3rd in Chicago, Illinois. The company will be located at booth #7004 in Hall B of the North Building.

“With the current revision of the United States Preventive Services Task Force guidelines for breast cancer screening, it has become even more important for the company to continue to take part in the scientific dialogue at meetings such as RSNA in order to emphasize the ability of CTLM to detect mammographically occult breast cancers in women classified with dense breast and the potentially very significant future role of CTLM as a screening modality also for women under the age of 50.. ,” stated Karsten Damgaard-Iversen, IDSI/Managment Consultant to the board of directors.

According to the RSNA Daily Bulletin, attendance for the 95th annual scientific assembly, meeting, and technical exhibition is expected to be between 57,000 and 60,000, the highest number of registered professionals ever. The Technical Exhibition at the RSNA annual meeting will welcome nearly 600 of the leading international healthcare companies, remaining the top healthcare exhibition in the U.S.

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

The Company is currently undergoing the clinical studies required for the Premarket approval application. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States.

For more information, visit our website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.